Genomic Health: predicting the course of an individual's can Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genomic Health: predicting the course of an individual's can

GHDX 63.44

0.0%

Nov 8 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	3/27/2007 1:44:31 PM
	of 38

AP Genomic Rises on Upgrade to 'Outperform' Tuesday March 27, 12:52 pm ET Genomic Health Up As Piper Jaffray Analyst Upgrades on Pipeline and Future of Oncotype Dx NEW YORK (AP) -- Genomic Health Inc. shares rose Tuesday after a Piper Jaffray analyst upgraded the stock to "Outperform," saying the company is optimistic about its future drugs and its breast cancer test Oncotype Dx. Analyst William Quirk raised his rating to "Outperform" from "Market Perform," and said the Redwood City, Calif.-based company expects to reach an agreement with the Food and Drug Administration about regulating Oncotype Dx. The test is a major source of revenue for the company, and sales of Oncotype doubled in 2006. Quirk held his target price at $23 per share. Genomics is developing colon cancer tests and a more detailed Oncotype product, Quirk said, and is working on tests with Sanofi-Aventis and ImClone Systems Inc. The tests will determine whether patients can benefit from Sanofi's Taxane and ImClone's Erbitux. Genomics shares jumped 89 cents, or 5.3 percent, to $17.69 in afternoon trading on the Nasdaq Stock Market. The stock has ranged from $9.60 to $24.68 over the past year

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next